«Влияние терапии бозентаном на клиническое состояние, гемодинамический статус, выраженность процессов ремоделирования правых и левых отделов сердца у больных с идиопатической легочной гипертензией» (стр. 25 )

62. Kukulski T., Hubbert L., Arnold M. et al. Normal regional right ventricular function and its change with age: a Doppler myocardial imaging study. J Am Soc Echocardiogr. 2000 Mar; 13(3):194-204.

63. Lafitte S., Pillois X., Reant P., et al. Estimation of pulmonary pressures and diagnosis of pulmonary hypertension by Doppler echocardiography: a retrospective comparison of routine echocardiography and invasive hemodynamics. J Am Soc Echocardiogr. 2013 May;26(5):457-63.

64. Lancellotti P., Budts W., De Wolf D., et al. Working Group on Non-Invasive Cardiac Imaging. Practical recommendations on the use of echocardiography to assess pulmonary arterial hypertension--a Belgian expert consensus endorsed by the Working Group on Non-Invasive Cardiac Imaging. Acta Cardiol. 2013 Feb;68(1):59-69.

65. Lang RM., Bierig M., Devereux RB., et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108.

121. Lindqvist P, Waldenstrom A, Henein M. et al. Regional and global right ventricular function in healthy individuals aged 20-90 years: a pulsed Doppler tissue imaging study: Umea General Population Heart Study. Echocardiography 2005;22:305-14.

66. Lotfi-Tokaldany M., Majidi S., Nikdoust F. et al. Normal values for longitudinal tissue velocity and strain rate imaging in individual segments of the left and right ventricles of healthy adult hearts. J Ultrasound Med. 2013 Mar;32(3):463-74.

123. Heimdal A. , Stoylen A. , Torp H. et al. Real-Time Strain Rate Imaging of the Left Ventricle by Ultrasound.  J Am Soc Echocardiography 1998;  11: 1013-1019.

67. Humbert M., Sitbon O., Chaouat A., et rvival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation. 2010; 122:156-163.

68. Masuda Y., Miyazaki H., Kondoh M., et al. Two different forms of endothelin receptors in rat lung. FEBS Lett 1989; 257:208–210.

69.Masuyama T, Kodama K, Kitabatake A. Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation 1986 Sep;74(3):484-92.

70. Matsuda M., Sekiguchi T., Sugishita Y., et al. Reliability of non-invasive estimates of pulmonary hypertension by pulsed Doppler echocardiography. Br Heart J. 1986 Aug;56(2):158-64.

71. Matsuoka Y, Hayakawa K. Noninvasive estimation of right ventricular systolic pressure in ventricular septal defect by a continuous wave Doppler technique. Jpn Circ J. 1986 Nov;50(11):1062-70.

72. McGoon M. D., Krichman A., Farber H. W., et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug;83(8):923-31.

73. McLaughlin V. V., Sitbon O., Badesch D. B., et rvival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25:244–249.

114. McLaughlin V., Stephen L. Archer, David B. Badesch, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. J Am Coll Cardiol. 2009;53(17):1573-1619.

74. Meluzэґn J., SЎpinarovaґ L., Bakala J., et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 2001; 22:340–348.

75. Meluzэґn J., SЎpinarovaґ L., DusЎek L., et al. Prognostic importance of the right ventricular function assessed by Doppler tissue imaging. Eur J Echocardiogr 2003; 4:262–271.

76. Micah R. Fisher, Paul R. Forfia, Elzbieta Chamera, et al. Accuracy of doppler Echocardiography in the Hemodynamic Assessment of pulmonary hypertension. Am. J. Respir. Crit. Care Med. April 1, 2009; 179(7): 615-621.

77. Michel R. P., Langleben D., Dupuis J. The endothelin system in pulmonary hypertension. Can J Physiol Pharmacol 2003; 81:542–554.

78. Migneault A., Sauvageau S., Villeneuve L., et al. Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide. Am J Respir Crit Care Med 2005; 171:506–513.

79. Musewe N. N., Poppe D., Smallhorn J. F., et al. Doppler echocardiographic measurement of pulmonary artery pressure from ductal Doppler velocities in the newborn. J Am Coll Cardiol. 1990 Feb;15(2):446-56.

80. Naeije R., Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995; 8:1445-1449.

81. Naito H., Arisawa J., Harada K., et al. Assessment of right ventricular regional contraction and comparison with the left ventricle in normal humans: a cine magnetic resonance study with

presaturation myocardial tagging. Br Heart J 1995; 74:186–191.

82. Navtej S. C., Tiong K. L., Piyush J. et al. Normative reference values for the tissue Doppler imaging parameters of left ventricular function: a population-based study.  Eur. J of Echocardiography 2010; 11: 51–56.

83. Okada O., Tanabe N., Yasuda J., et al Prediction of life expectancy in patients with primary pulmonary hypertension: a retrospective nationwide survey from 1980–1990. Intern Med 1999; 38, 12-68.

84. Panidis I. P., Ross. J, Mintz G. S. Effect of sampling site on assessment of pulmonary artery blood flow by Doppler echocardiography. Am J Cardiol. 1986 Nov 15;58(11):1145–1147.

85. Paulus W. J., Tschope C., Sanderson J. E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539–2550.

86. Perrone S., De La Fuente R. L., et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr 2002; 15:1160–1164.

87. Pilar Escribano-Subias, Isabel Blanco, Manuel Lуpez-Meseguer, et rvival in pulmonary hypertension in Spain: insights from the Spanish registry. ERJ September 1, 2012; 40(3): 596-603.

88. Provencher S., Sitbon O., Humbert M., et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27:589–595.

89. Raymond L. Benza; Dave P. Miller, Mardi Gomberg-Maitland, et al. Vascular Medicine. Predicting Survival in Pulmonary Arterial Hypertension. Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122:164-172.

90. Raymond R. J., Hinderliter A. L., Willis P. W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39:1214–1219.

91. Reeves J. T., Rubin L. J. The pulmonary circulation: snap shots of progress. Am J Respir Crit Care Med 1998; 157: s101–s108.

92. Rich J. D., Shah S. J., Swamy R. S., et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2011 May;139(5):988-93

93. Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers

on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.

94. Rich S., Rubin L. J., Abenhail L., et al. (1998). Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6–10, 1998). Geneva: The World Health Organization. Archived from the original on April 8, 2002.

95. Romberg E et al. Deutsches Archive Klinische Medizin 1891; 48:197-206.

96. Sakao S, Tanabe N, Kasahara Y. et rvival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. Intern Med. 2012;51(19):2721-6. Epub 2012 Oct 1.

97. Sandoval J., Bauerele O., Palomar A., et rvival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994; 89:1733-1744.

98. Sauvageau S., Thorin E., Caron A., et al. Endothelin-1- induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 2007; 44:375–381.

99. Sauvageau S., Thorin E., Caron A., et al. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 2006; 231: 840–846.

100. Schattke S., Knebel F., Grohmann A., et al. Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler tissue and speckle tracking echocardiography study. Cardiovascular Ultrasound 2010; 8:3–11.

101. Sitbon O., Badesch D. B., Channick R. N.. Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients with Pulmonary Arterial Hypertension. Chest 2003; 124:247-254.

102. Shirai Y, Yasuoka H, Okano Y. et al. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. Rheumatology (Oxford). 2012 Oct;51(10):1846-54. Epub 2012 Jun 26.

103. Shi-Wen X., Chen Y., Denton C. P., et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent  pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707–2719.

104. Shi-Wen X., Rodrнguez-Pascual F., Lamas S., et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol. 2006 Jul;26(14):5518-27.

105. Simonneau G., Robbins I., Beghetti M. et al. Update clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; S43-S54.

106. Sitbon O., McLaughlin V. V., Badesch D. B., et rvival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60:1025–1030.

107. Snell G. I., Salamonsen R. F., Bergin P., et al. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1263–1266.

108. Skjaerpe T. and Hatle L. Noninvasive estimation of systolic pressure in the right ventricle in patients with tricuspid regurgitation. Eur Heart J (1986) 7 (8):704-710.

therland G. R., Di Salvo G., Claus P. et al. Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function. J Am Soc Echocardiogr.  2004 Jul;17(7):788-802.

109. T. Thenappan, S. J. Shah, S. Rich, et rvival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. ERJ May 1, 2010; 35 (5):1079-1087.

110. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J. Cardiol. 1995; 26:135-136.

111. Torbicki A., Kurzyna M., Ciurzynski M., et al. Proximal pulmonary emboli modify right ventricular ejection pattern. Eur Respir J. 1999 Mar;13(3):616-21.

112. Torbicki A., Tramarin R., Fracchia C., et al. Reliability of pulsed wave Doppler monitoring of acute changes in pulmonary artery pressure in patients with chronic obstructive pulmonary disease. Prog Respir Res 1990; 26:133–141.

113. Turkevich D., Groves B. M., Micco A., et al. Early partial systolic closure of the pulmonic valve relates to severity of pulmonary hypertension. Am Heart J. 1988 Feb;115(2):409-18.

115. Vogel M., Schmidt M. R., Kristiansen S. B., et al. Validation of myocardial acceleration during isovolumic contraction as a novel noninvasive index of right ventricular contractility: comparison with ventricular pressure–volume relations in an animal model. Circulation 2002; 105:1693–1699.

122. Vogel M, Vogt M. Noninvasive assessment of right ventricular contractile performance. Congenital diseases in the right heart. London: Springer;2009.pp.207-12.

116. Wang B., Feng Y., Jia L. Q., et al. Accuracy of Doppler echocardiography in the assessment of pulmonary arterial hypertension in patients with congenital heart disease. Eur Rev Med Pharmacol Sci. 2013 Apr;17(7):923-8.

117. William H. Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus, 1628.

118. Williamson D. J., Wallman L. L., Jones R., et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102:411–418.

125. Xiang-dong YOU, Zhao-xia P. U., Xian-jing P. et al. Tissue Doppler imaging study of right ventricular myocardial systolic activation in subjects with pulmonary arterial hypertension. Chin Med J 2007; 120 (13):1172-1175.

119. Yeo T. C., Dujardin K. S., Tei C., et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81:1157–1161.

120. Yi Ling, Martin K., Johnson, et al. Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland. Am. J. Respir. Crit. Care Med. October 15, 2012; 186(8): 790-796.

126. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70:657-662.